All In Biotech

Drug Trial Radar · NCT01151540

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Last checked: Nov 19, 2026Latest source record: Mar 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

54

Actual

Start

Nov 2010

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Jun 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.

Conditions

  • Lennox-Gastaut Syndrome

Interventions

  • RufinamideDrug

    The target dosage is approximately 45 mg/kg/day, taken orally twice a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability of RufinamideTime frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 years 10 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Okayama, Japan

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Fukuoka, Fukuoka, Japan

  • Site not named

    Hiroshima, Hiroshima, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Goshi^shi, Kumamoto, Japan

  • Site not named

    Iwanuma-shi, Miyagi, Japan

  • Site not named

    Ōmura, Nagasaki, Japan

  • Site not named

    Nara, Nara, Japan

  • Site not named

    Niigata, Niigata, Japan

  • Site not named

    Yufu-shi, Oita Prefecture, Japan

  • Site not named

    Neyagawa, Osaka, Japan

  • Site not named

    Osaka, Osaka, Japan

  • Site not named

    Suita-shi, Osaka, Japan

  • Site not named

    Moriyama-shi, Shiga, Japan

  • Site not named

    Shizuoka, Shizuoka, Japan

  • Site not named

    Kodaira, Tokyo, Japan

  • Site not named

    Kokubunji-shi, Tokyo, Japan

  • Site not named

    Shinjuku, Tokyo, Japan

  • Site not named

    Toyoma-shi, Toyama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.